Inotec AMD, behind continuous topical oxygen therapy for advanced wound care NATROX, has appointed Gordie Nye as chairman of the board.
Nye has enjoyed a career across innovative healthcare and technology companies.
The HealthTech says Nye’s leadership is set to drive its mission to transform advanced wound care.
“We are thrilled to welcome Gordie as Chairman of the Board,” said Craig Kennedy, CEO of Inotec AMD.
“His remarkable experience and strategic insights will be invaluable as we continue to expand the impact of NATROX Wound Care and drive innovation in advanced wound care.”
Nye added: “I am honored to join Inotec AMD at such a pivotal time. The company’s commitment to harnessing the healing power of oxygen to improve patient outcomes is truly inspiring.
“I look forward to working closely with Craig and the talented team to further our mission and make a meaningful difference in advanced wound care.”
Nye’s appointment comes as NATROX Wound Care looks to enhance its leadership team with world-class expertise.
His career includes serving as CEO and director of ZELTIQ Aesthetics, as well as chairman and acting head of US Operations at Atlantic Therapeutics.
He currently serves as chairman of the board of managers at Journey Biosciences, fractional CEO & director at INVI IVF, and chairman of the board at LUUM Precision Lash.
The news arrives a month after the Cambridge-based firm received a £26m Series C investment to secure national reimbursement Stateside for NATROX O₂, which delivers continuous flow of oxygen directly to wound.
Inotec – NATROX® O₂ device heals wounds with humidified oxygen